Whatever the case, the results warrant future studies exploring CD5 targeting to improve the efficacy of currently available immunotherapeutic approaches against cancer such as IL-10 [35], TGF-β inhibitors [36] or IL-2/anti-IL-2 mAb immunocomplexes [37]. This evidence concerns the gene TGFB1 and cancer.